MA51568A - Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central - Google Patents

Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central

Info

Publication number
MA51568A
MA51568A MA051568A MA51568A MA51568A MA 51568 A MA51568 A MA 51568A MA 051568 A MA051568 A MA 051568A MA 51568 A MA51568 A MA 51568A MA 51568 A MA51568 A MA 51568A
Authority
MA
Morocco
Prior art keywords
pregnan
thia
aza
oxa
alpha
Prior art date
Application number
MA051568A
Other languages
English (en)
French (fr)
Inventor
Maria Jesus Blanco-Pillado
Boyd L Harrison
Daniel La
Albert Jean Robichaud
Francesco G Salituro
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA51568A publication Critical patent/MA51568A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/006—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by sulfur as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MA051568A 2018-01-12 2019-01-11 Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central MA51568A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862617134P 2018-01-12 2018-01-12
US201862616768P 2018-01-12 2018-01-12
US201862728514P 2018-09-07 2018-09-07

Publications (1)

Publication Number Publication Date
MA51568A true MA51568A (fr) 2021-04-21

Family

ID=65324563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051568A MA51568A (fr) 2018-01-12 2019-01-11 Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central

Country Status (6)

Country Link
US (3) US11718642B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706761A3 (cg-RX-API-DMAC7.html)
JP (3) JP7538040B2 (cg-RX-API-DMAC7.html)
MA (1) MA51568A (cg-RX-API-DMAC7.html)
TW (2) TW202612704A (cg-RX-API-DMAC7.html)
WO (1) WO2019140272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN111233815B (zh) * 2020-01-21 2022-10-14 上海应用技术大学 一种异阿根廷蚁素的制备方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN109503694A (zh) 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
CN113272315B (zh) 2018-12-26 2023-08-08 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
JP2025106370A (ja) 2025-07-15
JP7817214B2 (ja) 2026-02-18
EP3737687B1 (en) 2025-10-22
JP2023145726A (ja) 2023-10-11
WO2019140272A1 (en) 2019-07-18
US20260078143A1 (en) 2026-03-19
US20240150393A1 (en) 2024-05-09
TW201930269A (zh) 2019-08-01
JP2021510695A (ja) 2021-04-30
TW202612704A (zh) 2026-04-01
US12421275B2 (en) 2025-09-23
EP3737687A1 (en) 2020-11-18
US20200354399A1 (en) 2020-11-12
EP4706761A3 (en) 2026-05-06
EP4706761A2 (en) 2026-03-11
US11718642B2 (en) 2023-08-08
JP7538040B2 (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
EP3448389A4 (en) CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER
EP3720553A4 (en) PHOTOBIOMODULATION DEVICE FOR TREATMENT OF RETINAL DISEASES
MX2020009668A (es) Métodos novedosos.
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
EP3484577A4 (en) METHODS AND SYSTEMS FOR TREATING PELVIC DISEASES AND PAIN CONDITIONS
EP3615521A4 (en) METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
EP3704108A4 (en) COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGICAL DISORDERS
EP3400061A4 (en) LIGHT THERAPY SYSTEM FOR THE TREATMENT OF NASAL DISEASES
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3429605A4 (en) THERAPEUTIC FOR THE TREATMENT OF DISEASES INCLUDING THE CENTRAL NERVOUS SYSTEM
EP3774743A4 (en) PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND USED IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EP3481385C0 (en) Pulsatile drug delivery system for the treatment of morning akinesia
EP3440083A4 (en) IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3831821A4 (en) COMPOUND FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND ITS USE
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3856168A4 (en) COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
KR102228571B9 (ko) 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
EP3883552A4 (en) CYANOARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
EP3710015A4 (en) USE OF SRSF3 INGREDIENTS FOR TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES, CANCER, BACTERIAL OR VIRAL INFECTIONS
EP3856198A4 (en) Low-intensity treatment of hematological disorders
EP4132489A4 (en) Hydroxyureamethyl-acylfulvene for treating brain cancer or cns cancer